Table 3.
Change in DAS28-ESR scores over a 6-month period.
| Treatment as monotherapy or in combination |
n | Month 0 mean (SEM) |
Month 6 mean (SEM) |
Change over time value (%) |
P value |
|---|---|---|---|---|---|
| Methotrexate | 1,850 | 3.19 (0.03) | 2.89 (0.03) | 0.30 (9.4%) | <0.001 |
| Hydroxychloroquine | 494 | 3.33 (0.06) | 3.01 (0.06) | 0.32 (9.6%) | <0.001 |
| Leflunomide | 472 | 3.53 (0.07) | 3.04 (0.06) | 0.49 (13.8%) | <0.001 |
| Sulfasalazine | 319 | 3.55 (0.09) | 3.09 (0.08) | 0.46 (12.9%) | <0.001 |
|
| |||||
| Adalimumab | 324 | 2.96 (0.07) | 2.86 (0.06) | 0.10 (3.4%) | 0.106 |
| Etanercept | 394 | 3.15 (0.07) | 2.87 (0.06) | 0.28 (8.9%) | <0.001 |
| Tocilizumab | 128 | 2.51 (0.112) | 2.16 (0.10) | 0.35 (13.9%) | 0.001 |